Status:
COMPLETED
Bone Marrow Derived AC 133+ and Mono-Nuclear Cells (MNC) Implantation in Myocardial Infarction (MI) Patient
Lead Sponsor:
Royan Institute
Conditions:
Myocardial Infarction
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
PHASE3
Brief Summary
Although a percutaneous coronary intervention (PCI) can be used to open up the blocked artery and restore blood flow to the heart muscle after myocardial infarction, there may be a significant amount ...
Detailed Description
Patient from both gender, who had acute MI within recent 3 Weeks in LAD territory and would underwent PCI are eligible for this study. The bone marrow derived AC 133+ and MNC would be intracoronary in...
Eligibility Criteria
Inclusion
- BMI\> 30
- First acute MI in LAD territory
- St elevation MI
- Ejection fraction: 20-45%
- at least two non - mobile or less mobile segment of left ventricular myocard.
- Successful PCI with stenting
Exclusion
- Multivessel ceremony artery disease
- Pulmonary edema
- SBP \< 80 mmHg
- Thrombocytopenia (PLT \< 50, 000)
- INR \> 2
- Hepatic failure or dysfunction
- Renal failure or dysfunction
- Positive HIV Ab/ HBC Ab/ HCV Ab/ HSV Ag
- Documental terminal illness
- Documental Malignancy
- Patient with sever coronary disease and unstability of vital sign
- History of leukopenia, Anemia, hepatic or renal dysfunction or malignancy
Key Trial Info
Start Date :
May 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2012
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT01187654
Start Date
May 1 2009
End Date
December 1 2012
Last Update
December 27 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Royan institute
Tehran, Iran